Recombinant platelet factor-4 data

Phase I data showed no adverse reactions to the use of the agent in 18 patients who received heparin for cardiac catheterization. Three doses were tested over one or three minutes of infusion.

The conclusion that the drug safely reversed the anti-clotting action of heparin will allow the start of a Phase I trial in bypass surgery, and a Phase II trial in cardiac catheterization, RGEN said. ...